成人超重与肥胖的药物治疗:随机对照试验的系统综述与网络Meta分析
该系统综述与网络Meta分析检索PubMed、Embase和Cochrane Library建库至2021年3月23日的随机对照试验,纳入143项试验共49810名超重或肥胖成人,评估减重药物的获益与危害。与单纯生活方式干预相比,除左卡尼汀外所有药物均降低体重;芬特明-托吡酯和GLP-1受体激动剂减重效果最佳,其中司美格鲁肽可能最有效。
要点
- 与单纯生活方式干预相比,除左卡尼汀外所有药物均降低体重。
- 芬特明-托吡酯减重效果最佳(≥5%减重OR 8.02,体重变化MD -7.97),其次为GLP-1受体激动剂(OR 6.33,MD -5.76)。
- 纳曲酮-安非他酮、芬特明-托吡酯、GLP-1受体激动剂和奥利司他与导致停药的不良事件增加相关。
核心结论
- 在超重和肥胖成人中,芬特明-托吡酯和GLP-1受体激动剂是减重效果最好的药物;在GLP-1受体激动剂中,司美格鲁肽可能最有效。
研究设计与样本
- 系统综述与网络Meta分析,检索PubMed、Embase和Cochrane Library(CENTRAL)自建库至2021年3月23日的随机对照试验。
- 共纳入143项符合条件的试验,合计49810名超重或肥胖成人受试者。
- 采用频率学派随机效应网络Meta分析,并应用GRADE框架评价证据确定性、计算绝对效应、对干预措施分类并呈现结果。
- 研究注册于PROSPERO,注册号CRD 42021245678。
主要发现
- 检索共识别14605条文献,最终纳入143项试验、49810名受试者。
- 除左卡尼汀外,所有药物与单纯生活方式干预相比均降低体重;以下数值均指与单纯生活方式干预的比较。
- 高至中等确定性证据显示芬特明-托吡酯减重效果最佳(≥5%减重的OR 8.02,95%CI 5.24至12.27;体重变化百分比MD -7.97,95%CI -9.28至-6.66),其次为GLP-1受体激动剂(OR 6.33,95%CI 5.00至8.00;MD -5.76,95%CI -6.30至-5.21)。
- 纳曲酮-安非他酮(OR 2.69,95%CI 2.11至3.43)、芬特明-托吡酯(OR 2.40,95%CI 1.69至3.42)、GLP-1受体激动剂(OR 2.17,95%CI 1.71至2.77)和奥利司他(OR 1.72,95%CI 1.44至2.05)与导致停药的不良事件增加相关。
- 事后分析中,GLP-1受体激动剂司美格鲁肽的获益明显大于其他药物,且不良事件风险与其他药物相似:≥5%减重的OR 9.82(95%CI 7.09至13.61),体重变化百分比MD -11.41(95%CI -12.54至-10.27)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Pharmacotherapy provides an option for adults with overweight and obesity to reduce their bodyweight if lifestyle modifications fail. We summarised the latest evidence for the benefits and harms of weight-lowering drugs. METHODS: This systematic review and network meta-analysis included searches of PubMed, Embase, and Cochrane Library (CENTRAL) from inception to March 23, 2021, for randomised controlled trials of weight-lowering drugs in adults with overweight and obesity. We performed frequentist random-effect network meta-analyses to summarise the evidence and applied the Grading of Recommendations Assessment, Development, and Evaluation frameworks to rate the certainty of evidence, calculate the absolute effects, categorise interventions, and present the findings. The study was registered with PROSPERO, CRD 42021245678. FINDINGS: 14 605 citations were identified by our search, of which 143 eligible trials enrolled 49 810 participants. Except for levocarnitine, all drugs lowered bodyweight compared with lifestyle modification alone; all subsequent numbers refer to comparisons with lifestyle modification. High to moderate certainty evidence established phentermine-topiramate as the most effective in lowering weight (odds ratio [OR] of ≥5% weight reduction 8·02, 95% CI 5·24 to 12·27; mean difference [MD] of percentage bodyweight change -7·97, 95% CI -9·28 to -6·66) followed by GLP-1 receptor agonists (OR 6·33, 95% CI 5·00 to 8·00; MD -5·76, 95% CI -6·30 to -5·21). Naltrexone-bupropion (OR 2·69, 95% CI 2·11 to 3·43), phentermine-topiramate (2·40, 1·69 to 3·42), GLP-1 receptor agonists (2·17, 1·71 to 2·77), and orlistat (1·72, 1·44 to 2·05) were associated with increased adverse events leading to drug discontinuation. In a post-hoc analysis, semaglutide, a GLP-1 receptor agonist, showed substantially larger benefits than other drugs with a similar risk of adverse events as other drugs for both likelihood of weight loss of 5% or more (OR 9·82, 95% CI 7·09 to 13·61) and percentage bodyweight change (MD -11·41, 95% CI -12·54 to -10·27). INTERPRETATION: In adults with overweight and obesity, phentermine-topiramate and GLP-1 receptor agonists proved the best drugs in reducing weight; of the GLP-1 agonists, semaglutide might be the most effective. FUNDING: 1.3.5 Project for Disciplines of Excellence, West China Hospital, Sichuan University.
引用
- Shi Q, Wang Y, Hao Q, et al. Pharmacotherapy for adults with overweight and obesity: a systematic review and network meta-analysis of randomised controlled trials. Lancet. 2021. PMID: 34895470. doi:10.1016/S0140-6736(21)01640-8
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。